Ligand Pharmaceuticals
LGND
222 hedge funds and large institutions have $1.21B invested in Ligand Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 63 increasing their positions, 72 reducing their positions, and 19 closing their positions.
223% more call options, than puts
Call options by funds: $7.41M | Put options by funds: $2.29M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
5% more funds holding
Funds holding: 211 → 222 (+11)
3% more capital invested
Capital invested by funds: $1.17B → $1.21B (+$38.4M)
0.55% less ownership
Funds ownership: 93.74% → 93.2% (-0.55%)
13% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$24.9M |
| 2 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$14.5M |
| 3 |
ZCM
Ziegler Capital Management
Chicago,
Illinois
|
+$6.13M |
| 4 |
DIA
Dana Investment Advisors
Waukesha,
Wisconsin
|
+$5.59M |
| 5 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$4.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$24.7M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$23.3M |
| 3 |
Morgan Stanley
New York
|
-$10.8M |
| 4 |
BlackRock
New York
|
-$6.93M |
| 5 |
Man Group
London,
United Kingdom
|
-$5.59M |
LGND Hedge Fund Activity: Q1 2024 in Review
222 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2024, worth a combined $1.21B — up 3.3% from $1.17B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LGND positions and 19 closed out — a net gain of 14 holders — while 63 added to existing stakes and 72 trimmed.
The largest buyer was Cardinal Capital Management LLC (Connecticut), adding an estimated $24.9M. The largest seller was Janus Henderson Group, cutting an estimated $24.7M.
- 222 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2024, up from 211 in Q4 2023.
- Funds reported $1.21B of Ligand Pharmaceuticals stock for Q1 2024, up 3.3% quarter-over-quarter.
- 33 funds opened new Ligand Pharmaceuticals positions in Q1 2024 and 19 closed out, a net change of +14 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2024 was Cardinal Capital Management LLC (Connecticut), an estimated $24.9M added.
- The largest Ligand Pharmaceuticals seller in Q1 2024 was Janus Henderson Group, an estimated $24.7M sold.
Based on aggregated 13F filings for Q1 2024.